bufalin has been researched along with Disease Models, Animal in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 4 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, Y; Ding, P; Duan, J; Gu, C; Guo, M; Li, N; Qiao, L; Shao, M; Sun, S; Tang, C; Tang, X; Wang, Y; Wei, R; Xiao, Y; Yang, Y; Zhang, L; Zhou, Y | 1 |
| Gao, R; Lv, Y; Wei, X; Xu, Y; Yang, C; Zou, S | 1 |
| Alexander, KM; Bähre, H; Bär, C; Batkai, S; Beaumont, J; Bock, K; Braesen, JH; Brandenberger, C; Dangwal, S; Diez, J; Do, QT; Fiedler, J; Fisch, S; Foinquinos, A; Geffers, R; González, A; Grote-Levi, L; Hobuß, L; Janssen-Peters, H; José, GS; Jung, M; Just, A; Kaever, V; Kenneweg, F; Kleemiss, F; Kreutzer, FP; Leonardy, J; Liao, R; López, B; Müller, DN; Ngoy, S; Pfanne, A; Piccoli, MT; Ravassa, S; Remke, J; Samolovac, S; Santer, L; Scherf, K; Schimmel, K; Schmitz, J; Thum, T; Wertheim, BM; Wilck, N; Xiao, K; Zimmer, K | 1 |
| Batkai, S; Einzinger, P; Gyöngyösi, M; Hasimbegovic, E; Kastner, N; Lukovic, D; Mester-Tonczar, J; Spannbauer, A; Thum, T; Traxler, D; Winkler, J; Zlabinger, K | 1 |
| He, X; Liu, C; Qiu, YY; Shi, XJ; Xu, K; Yin, PH; Yu, H; Yuan, YX; Yuan, ZT; Zou, Y | 1 |
| Chi, H; Meng, Z; Wang, H; Zhang, C | 1 |
6 other study(ies) available for bufalin and Disease Models, Animal
| Article | Year |
|---|---|
AHSA1 is a promising therapeutic target for cellular proliferation and proteasome inhibitor resistance in multiple myeloma.
Topics: Animals; Antineoplastic Agents; Bufanolides; Cell Proliferation; Disease Models, Animal; Gene Expression Profiling; Humans; Mice; Mice, Inbred NOD; Molecular Chaperones; Multiple Myeloma; Proteasome Inhibitors; Transfection | 2022 |
Bufalin reduces myocardial infarction-induced myocardial fibrosis and improves cardiac function by inhibiting the NLRP3/IL-1β signalling pathway.
Topics: Animals; Disease Models, Animal; Fibrosis; Inflammasomes; Interleukin-1beta; Male; Mice; Mice, Inbred C57BL; Myocardial Infarction; NLR Family, Pyrin Domain-Containing 3 Protein; Stroke Volume; Sulfonamides; Ventricular Function, Left | 2023 |
Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction.
Topics: Amaryllidaceae Alkaloids; Animals; Apoptosis; Bufanolides; Cardiomyopathies; Cardiovascular Agents; Cell Proliferation; Cells, Cultured; Diastole; Disease Models, Animal; Extracellular Matrix; Fibroblasts; Fibrosis; High-Throughput Screening Assays; Humans; Hypertension; Male; Mice, Inbred C57BL; MicroRNAs; Myocardium; Phenanthridines; Rats, Inbred Dahl; Selenoprotein P; Ventricular Function, Left | 2020 |
Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine.
Topics: Amaryllidaceae Alkaloids; Animals; Bufanolides; Disease Models, Animal; Humans; Injections, Subcutaneous; Male; Myocardial Infarction; Phenanthridines; RNA, Circular; RNA, Long Noncoding; Stroke Volume; Swine; Treatment Outcome; Up-Regulation; Ventricular Remodeling | 2020 |
Bufalin reverses ABCB1-mediated drug resistance in colorectal cancer.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bufanolides; Cell Line, Tumor; Cell Membrane Permeability; Colorectal Neoplasms; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Enzyme Activation; Gene Expression Regulation, Neoplastic; Humans; Mice; Models, Molecular; Molecular Conformation; Protein Binding; Xenograft Model Antitumor Assays | 2017 |
Synergistic anticancer effects of bufalin and sorafenib by regulating apoptosis associated proteins.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bufanolides; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; Humans; Male; Mice; Neoplasms; Niacinamide; Phenylurea Compounds; Sorafenib; Xenograft Model Antitumor Assays | 2018 |